Biologic services demand pushes BioOutsource to open new Glasgow facility

By Zachary Brennan contact

- Last updated on GMT

A look at the new Glasgow facility
A look at the new Glasgow facility

Related tags: Monoclonal antibodies

A surge of demand in biologics contract testing and biosimilar characterization has caused BioOutsource to double its capacity with the opening of a new facility in Glasgow, Scotland.

The Scottish company offers a range of development and manufacturing services for recombinant proteins, monoclonal antibodies, biosimilars, regenerative medicine, gene therapy vectors and vaccines. The opening of this new facility will create about 50 new jobs in the next six months.

Our opening of this new, state-of-the-art facility demonstrates our commitment to our growing list of global customers​,” said BioOutsource CEO Gerry MacKay. “Demand for our services remains high and we are doubling our capacity to make sure we are ready to support the robust pipeline of biotech and biosimilar products currently in development​.”

The company’s current partnerships and clients include work with Actavis Biologics, Oncobiologics and MediWound.

Spokeswoman Gemma Fulton told us the company is seeing particularly strong growth in the characterization and comparability testing services it provides for biosimilar drug candidates.

The company offers off-the-shelf assay packages to complete a comparability study for the biological characterisation of a range of biosimilar molecules, including for Herceptin (trastuzumab), Humira (adalimumab), Enbrel (etanercept), Remicade (infliximab) and others. In addition, the company supports biosafety testing, lot release and stability and development of custom Phase III host cell protein assays.

As biopharma companies expand their focus on biosimilars, the requirement for off-the-shelf assays to rapidly characterise the candidate molecules in their pipelines has increased​,” Fulton added.

The new Scottish facility comes three months after the company was acquired by Sartorius Stedim Biotech​. And a little more than a year ago, BioOutsource expanded into the US​ with a new Cambridge, Massachusetts sales office. The company told us that it’s seeing its highest growth in biosimilar testing come from the US market.

The company currently employs about 80 others and reported annual revenues of around $10m last year.

Related news

Related products

show more

Liver Disease Capabilities

Liver Disease Capabilities

Q² Solutions | 01-Oct-2020 | Clinical Study

We integrate therapeutic insights, state-of-the-art technologies, best-in-class methods and quality systems to optimize NAFLD & NASH study design,...

Innovations in OSD

Innovations in OSD

Recorded the 06-Oct-2020 | Webinar

This DFE series of educational webinars looks at innovations in Oral Solid Dose Forms with the emergence of advanced technologies such as Continuous Manufacturing...

Register for free

CAR-T Cell Therapy

CAR-T Cell Therapy

Q² Solutions | 01-Sep-2020 | Clinical Study

Cell therapy involves the transfer of genetically altered cells into a patient. As a global central laboratory services organization, we provide testing...

Related suppliers

Follow us


View more